Expanding Radiopharmaceutical Targeting Mechanisms with Novel Moieties to Harness Enhanced Specificity, Efficacy & Safety
Time: 11:00 am
day: Workshop B
Details:
The development of novel targeting moieties for radiopharmaceuticals has seen significant advancements, particularly in the context of targeting cancer cells and supporting tissues. These novel moieties include small peptides, cyclic peptides, bispecifics and nanobodies, each offering unique advantages in terms of specificity, stability, and pharmacokinetics.
Uncovering the latest understandings and developments across novel targeting approaches, this
workshop will:
- Reveal more novel small peptides for enhanced specificity, affinity and rapid clearance
- Explore cyclic peptides for degradation resistance, improved binding and extended circulation time
- Interrogate nanobodies for better tissue penetration and rapid clearance and high stability
- Maximisebispecific antibodies for synergistic effects
- Examine existing targeting mechanisms such as antibodies and antibody fragments to assess their viability as isotope conjugates
- What should you be looking for to understand what makes a good targeting moiety
